Manfred is a member of the office of the Chief Scientific Officer, focusing on the establishment of cross-therapeutic platforms providing scientific and medical support for INC Research/inVentiv Health customers.
In 2011 he has established and since then leads INC Research/inVentiv Health Biosimilar Consortium, a team of experts actively engaged in the development of biosimilars from regulatory consulting, clinical operations, therapeutic business units, market access consulting, and real-world evidence.
In his function as head of the Biosimilar Consortium, he supports customers in the overall clinical development of biosimilar, incl. selection of patient population, indication and endpoints, as well as the operational conduct. Manfred is also frequently attending meetings with FDA and EMA discussing biosimilar development strategies, and thus is abreast of the latest regulatory requirements and thinking of the agencies.
Manfred has held leading roles in the CRO industry for the last ten years and worked in the Life Sciences area for over 20 years.
He holds a PhD in Molecular Biology from University of Bonn, Germany.